FDA updates duodenoscope surveillance protocols

Published: 27-Feb-2018
Regulatory

The US Food and Drug Administration will host a webinar in March focusing on new voluntary duodenoscope reprocessing protocols

The US Food and Drug Administration (FDA) has announced the availability of voluntary, standardised duodenoscope surveillance sampling and culturing protocols. The Centers for Disease Control and Prevention (CDC) and American Society for Microbiology (ASM) along with other endoscope culturing experts are backing the initiative.

These protocols are an update to the Interim Duodenoscope Surveillance Protocol released by CDC in March 2015.

Hospitals and health care facilities that use duodenoscopes can, in addition to meticulously following manufacturer reprocessing instructions, take these additional steps to further reduce the risk of infection and increase the safety of these medical devices.

Duodenoscopes are flexible, lighted tubes that are used to treat patients undergoing endoscopic retrograde cholangiopancreatography (ECRP). These procedures often are life-saving and are the least invasive way of draining fluids from pancreatic and biliary ducts blocked by cancerous tumors, gallstones or other conditions.

Disinfection procedure

More than 500,000 ERCPs are performed each year in the United States. Duodenoscopes undergo a multi-step cleaning and high-level disinfection procedure called reprocessing so that they can be reused between patients. However, the complex design of duodenoscopes makes it difficult to remove contaminants compared to other types of endoscopes. If not thoroughly cleaned and disinfected, tissue or fluid from one patient can remain in a duodenoscope when it is used on a subsequent patient. In rare cases, this can lead to patient-to-patient infection.

Microbiological sampling and culturing of duodenoscopes involves sampling duodenoscope channels as well as the distal end of the endoscope and then culturing those samples with the goal of detecting bacterial contamination that may be present on the duodenoscope after reprocessing.

The FDA, CDC, ASM and other endoscope culturing experts will meet in a webinar (March 22, 2018) from 1-2:30pm (Eastern Time) to learn more about the voluntary duodenoscope surveillance sampling and culturing protocols.

The webinar has been designed to help facilities monitor the quality of their reprocessing procedures.

  • Companies:
  • US Food and Drug Administration (FDA)
  • Centers for Disease Control and Prevention
See more

You may also like

Regulatory

Interview with FDA Press Officer Charles Kohler from CDER

Read more
The FDA Press Officer from CDER talks about how to navigate the compliance pathways for those in the pharmaceutical industry. Written by Tom McGhie from Cleanroom Technology

Trending Articles

  1. What is ISO 8 cleanroom classification? Each cleanroom class is denoted by a maximum concentration of particles per cubic meter or cubic foot of air. ISO 8 is the second lowest cleanroom classification
  2. Medicinal cannabis: What it takes to be GMP-ready The legalisation of cannabis for medicinal purposes pushes producers to supply chemists, physicians and patients with the newly approved drug in accordance with good manufacturing and distribution practices, as Dr Andrea Kühn-Hebecker explains
  3. Starting a sterile compounding pharmacy Modular cleanroom expert Mecart provides a step-by-step guide to sterile compounding pharmacy as recommended by pharmacy regulatory inspectors
  4. IPS appoints Jim Stephanou as new CEO Stephanou is an accomplished leader in the pharmaceutical industry with over thirty years of experience in manufacturing operations and engineering
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    EU GMP Annex 15 Revisions: Improving Qualification and Validation Validation and qualification form an important part of the quality system in the pharmaceutical sector and can be defined in different ways. Tim Sandle, Head of Microbiology, BPL, UK discusses some standard definitions from a Good Manufacturing Practice (GMP) perspective

Upcoming event

Lounges

23-25 April 2024 | Conference | Messe Karlsruhe, Germany See all

You may also like

Regulatory

Interview with FDA Press Officer Charles Kohler from CDER

The FDA Press Officer from CDER talks about how to navigate the compliance pathways for those in the pharmaceutical industry. Written by Tom McGhie from Cleanroom Technology
Regulatory

FDA Warning Letter: ImprimisRx facility features stained HEPA filters

Following a 2022 inspection, ophthalmic medicine production expert ImprimisRx received a 483 form. A year later a warning letter has been sent emphasising major issues with the facility design and operation
Regulatory

Warning Letters: Lessons from an FDA Captain

Redica Systems’ Jerry Chapman talks to FDA's Ileana Barreto-Pettit
Regulatory

Abraxis Bioscience receives FDA warning

During the examination, FDA officials found that the company “failed to thoroughly investigate any unexplained discrepancy or failure of a batch”
Regulatory

FDA gives out 483 form to Torrent Pharma citing "inadaquate cleaning procedure"

The pharma giant from India has been give the form citing three main issues
Regulatory

Strides Pharma passes US FDA inspection at Singapore facility

The global pharma company has completed the inspection with zero 483 observations
Regulatory

FDA "strongly recommends" Syntec engage a GMP consultant after warning letter

Syntec Pharma has received notice from the US agency for reasons that include using laundry detergent as a ventilation hood cleaning agent
Subscribe now